FutuRx

Dr. Kinneret Savitzky serves as CEO and leads the incubator's investment and company-formation decisions. The management team includes Chief Business Officer Modi Teicher and Chief Technology Officer Aric Orbach. Strategic input likely flows from the incubator's pharmaceutical backers, though the executive team in Ness Ziona drives day-to-day portfolio construction.

FutuRx sources therapeutic programs primarily from the Weizmann Institute of Science, working closely with its technology transfer office, Yeda. It also reviews assets from other Israeli universities and research hospitals. The incubator's physical location in the Weizmann Science Park enables early access to academic discoveries before they are broadly marketed to external venture investors.

FutuRx is a biotechnology incubator, not a family office. It functions as a hybrid asset manager that forms and seeds new companies rather than acquiring stakes in existing ones. Its model is backed by a consortium of corporate pharmaceutical partners and institutional life-sciences investors, distinguishing it from both traditional venture capital firms and family-run investment offices.

FutuRx primarily creates and seeds new portfolio companies from academic intellectual property rather than making fund commitments to outside managers. Each incubated startup receives lab space, management support, and initial capital within the Ness Ziona facility. The firm is not known to operate a fund-of-funds program or allocate capital to third-party venture vehicles.

The incubator has historically focused on oncology, immunology, and neuroscience, reflecting both the strengths of the Weizmann Institute and the strategic interests of its pharmaceutical limited partners. Individual portfolio companies have pursued small-molecule drugs, biologics, and platform technologies. FutuRx's mandate supports preclinical and early clinical-stage programs with clear paths to pharmaceutical partnerships or acquisitions.

FutuRx is a separate legal entity but operates as a close collaborator of the Weizmann Institute. Its laboratory and offices are located in the Weizmann Science Park in Ness Ziona. The incubator licenses intellectual property from Weizmann through Yeda, the institute's technology transfer arm, and commercializes academic research through newly formed companies.

FutuRx typically forms companies at inception as the lead or sole institutional sponsor during the incubation phase. As portfolio companies mature toward Series A financings, external venture capital firms often co-invest or lead subsequent rounds. The incubator's consortium structure — with OrbiMed, Takeda, and Johnson & Johnson Innovation as backers — reduces the need to seek outside co-investors at the earliest stages.